APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gabapentin

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.

Selected research

Market Outlook & Growth Opportunities

Global Gabapentin Market Outlook and Growth Opportunities 2026

21 December 2025202 pages

Choose your research edition.

Industry ResearchGabapentin Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Gabapentin Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Gabapentin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gabapentin Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Gabapentin Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.

Global Gabapentin key players include Novartis, TEVA, Mylan, Pfizer, etc. Global top four manufacturers hold a share about 20%.

North America is the largest market, with a share over 30%, followed by Asia-Pacific, and Europe, both have a share about 50 percent.

Read the full market overview

In terms of product, Capsule is the largest segment, with a share about 55%. And in terms of application, the largest application is Epilepsy, followed by Neuropathic Pain, Restless Legs Syndrome, etc.

This report provides an overview of the global Gabapentin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gabapentin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gabapentin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gabapentin market size, projected growth trends, production technologies, key applications, and end-use industries.

Gabapentin Segment by Company

Pfizer

Assertio Therapeutics

TEVA

Mylan

Arbor Pharma

Novartis

Apotex

Sun Pharmaceutical

Aurobindo Pharma

Intas

Amneal

Marksans Pharma

Glenmark

Alkem

Jiangsu Enhua

Jiangsu Hengrui

Sailike

Gabapentin Segment by Type

Capsule

Tablet

Gabapentin Segment by Application

Epilepsy

Neuropathic Pain

Restless Legs Syndrome

Others

Gabapentin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gabapentin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gabapentin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gabapentin significant trends, drivers, influence factors in global and regions.

6. To analyze Gabapentin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gabapentin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gabapentin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gabapentin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gabapentin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gabapentin industry.

Chapter 3: Detailed analysis of Gabapentin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gabapentin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gabapentin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gabapentin Industry Trends Table 2. Gabapentin Industry Drivers Table 3. Gabapentin Industry Opportunities and Challenges Table 4. Gabapentin Industry Restraints Table 5. Global Gabapentin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gabapentin Revenue Share by Company (2021-2026) Table 7. Global Gabapentin Sales Volume by Company (M Unit) & (2021-2026) Table 8. Global Gabapentin Sales Volume Share by Company (2021-2026) Table 9. Global Gabapentin Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Gabapentin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gabapentin Key Company Manufacturing Base & Headquarters Table 12. Global Gabapentin Company, Product Type & Application Table 13. Global Gabapentin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gabapentin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Capsule Table 18. Significant Companies of Tablet Table 19. Global Gabapentin Sales Volume by Type 2021 VS 2025 VS 2032 (M Unit) Table 20. Global Gabapentin Sales Volume by Type (2021-2026) & (M Unit) Table 21. Global Gabapentin Sales Volume by Type (2027-2032) & (M Unit) Table 22. Global Gabapentin Sales Volume Share by Type (2021-2026) Table 23. Global Gabapentin Sales Volume Share by Type (2027-2032) Table 24. Global Gabapentin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Gabapentin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Gabapentin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Gabapentin Sales Value Share by Type (2021-2026) Table 28. Global Gabapentin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Epilepsy Table 30. Significant Companies of Neuropathic Pain Table 31. Significant Companies of Restless Legs Syndrome Table 32. Significant Companies of Others Table 33. Global Gabapentin Sales Volume by Application 2021 VS 2025 VS 2032 (M Unit) Table 34. Global Gabapentin Sales Volume by Application (2021-2026) & (M Unit) Table 35. Global Gabapentin Sales Volume by Application (2027-2032) & (M Unit) Table 36. Global Gabapentin Sales Volume Share by Application (2021-2026) Table 37. Global Gabapentin Sales Volume Share by Application (2027-2032) Table 38. Global Gabapentin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Gabapentin Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Gabapentin Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Gabapentin Sales Value Share by Application (2021-2026) Table 42. Global Gabapentin Sales Value Share by Application (2027-2032) Table 43. Global Gabapentin Sales by Region: 2021 VS 2025 VS 2032 (M Unit) Table 44. Global Gabapentin Sales by Region (2021-2026) & (M Unit) Table 45. Global Gabapentin Sales Market Share by Region (2021-2026) Table 46. Global Gabapentin Sales by Region (2027-2032) & (M Unit) Table 47. Global Gabapentin Sales Market Share by Region (2027-2032) Table 48. Global Gabapentin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Gabapentin Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Gabapentin Sales Value Share by Region (2021-2026) Table 51. Global Gabapentin Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Gabapentin Sales Value Share by Region (2027-2032) Table 53. Global Gabapentin Market Average Price (USD/Unit) by Region (2021-2026) Table 54. Global Gabapentin Market Average Price (USD/Unit) by Region (2027-2032) Table 55. Global Gabapentin Sales by Country: 2021 VS 2025 VS 2032 (M Unit) Table 56. Global Gabapentin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Gabapentin Sales by Country (2021-2026) & (M Unit) Table 58. Global Gabapentin Sales Market Share by Country (2021-2026) Table 59. Global Gabapentin Sales by Country (2027-2032) & (M Unit) Table 60. Global Gabapentin Sales Market Share by Country (2027-2032) Table 61. Global Gabapentin Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Gabapentin Sales Value Market Share by Country (2021-2026) Table 63. Global Gabapentin Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Gabapentin Sales Value Market Share by Country (2027-2032) Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. Pfizer Gabapentin Product Portfolio Table 69. Pfizer Recent Development Table 70. Assertio Therapeutics Company Information Table 71. Assertio Therapeutics Business Overview Table 72. Assertio Therapeutics Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. Assertio Therapeutics Gabapentin Product Portfolio Table 74. Assertio Therapeutics Recent Development Table 75. TEVA Company Information Table 76. TEVA Business Overview Table 77. TEVA Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. TEVA Gabapentin Product Portfolio Table 79. TEVA Recent Development Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Mylan Gabapentin Product Portfolio Table 84. Mylan Recent Development Table 85. Arbor Pharma Company Information Table 86. Arbor Pharma Business Overview Table 87. Arbor Pharma Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Arbor Pharma Gabapentin Product Portfolio Table 89. Arbor Pharma Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Novartis Gabapentin Product Portfolio Table 94. Novartis Recent Development Table 95. Apotex Company Information Table 96. Apotex Business Overview Table 97. Apotex Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Apotex Gabapentin Product Portfolio Table 99. Apotex Recent Development Table 100. Sun Pharmaceutical Company Information Table 101. Sun Pharmaceutical Business Overview Table 102. Sun Pharmaceutical Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Sun Pharmaceutical Gabapentin Product Portfolio Table 104. Sun Pharmaceutical Recent Development Table 105. Aurobindo Pharma Company Information Table 106. Aurobindo Pharma Business Overview Table 107. Aurobindo Pharma Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Aurobindo Pharma Gabapentin Product Portfolio Table 109. Aurobindo Pharma Recent Development Table 110. Intas Company Information Table 111. Intas Business Overview Table 112. Intas Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Intas Gabapentin Product Portfolio Table 114. Intas Recent Development Table 115. Amneal Company Information Table 116. Amneal Business Overview Table 117. Amneal Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. Amneal Gabapentin Product Portfolio Table 119. Amneal Recent Development Table 120. Marksans Pharma Company Information Table 121. Marksans Pharma Business Overview Table 122. Marksans Pharma Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 123. Marksans Pharma Gabapentin Product Portfolio Table 124. Marksans Pharma Recent Development Table 125. Glenmark Company Information Table 126. Glenmark Business Overview Table 127. Glenmark Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 128. Glenmark Gabapentin Product Portfolio Table 129. Glenmark Recent Development Table 130. Alkem Company Information Table 131. Alkem Business Overview Table 132. Alkem Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 133. Alkem Gabapentin Product Portfolio Table 134. Alkem Recent Development Table 135. Jiangsu Enhua Company Information Table 136. Jiangsu Enhua Business Overview Table 137. Jiangsu Enhua Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 138. Jiangsu Enhua Gabapentin Product Portfolio Table 139. Jiangsu Enhua Recent Development Table 140. Jiangsu Hengrui Company Information Table 141. Jiangsu Hengrui Business Overview Table 142. Jiangsu Hengrui Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 143. Jiangsu Hengrui Gabapentin Product Portfolio Table 144. Jiangsu Hengrui Recent Development Table 145. Sailike Company Information Table 146. Sailike Business Overview Table 147. Sailike Gabapentin Sales (M Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 148. Sailike Gabapentin Product Portfolio Table 149. Sailike Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Gabapentin Distributors List Table 153. Gabapentin Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Gabapentin Product Image Figure 2. Global Gabapentin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gabapentin Sales (2021-2032) & (M Unit) Figure 5. Global Gabapentin Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Gabapentin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Capsule Image Figure 10. Tablet Image Figure 11. Global Gabapentin Sales Volume by Type (2021 VS 2025 VS 2032) & (M Unit) Figure 12. Global Gabapentin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Gabapentin Sales Volume Share by Type (2021-2032) Figure 14. Global Gabapentin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Gabapentin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Gabapentin Sales Value Share by Type (2021-2032) Figure 17. Epilepsy Image Figure 18. Neuropathic Pain Image Figure 19. Restless Legs Syndrome Image Figure 20. Others Image Figure 21. Global Gabapentin Sales Volume by Application (2021 VS 2025 VS 2032) & (M Unit) Figure 22. Global Gabapentin Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Gabapentin Sales Volume Share by Application (2021-2032) Figure 24. Global Gabapentin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Gabapentin Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Gabapentin Sales Value Share by Application (2021-2032) Figure 27. Global Gabapentin Sales by Region: 2021 VS 2025 VS 2032 (M Unit) Figure 28. Global Gabapentin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Gabapentin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Gabapentin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 32. North America Gabapentin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Gabapentin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Gabapentin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 38. South America Gabapentin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Gabapentin Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Gabapentin Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Gabapentin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Gabapentin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Gabapentin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Gabapentin Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Gabapentin Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Capsule
  • Tablet
Applications
  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others
Companies covered
  • Pfizer
  • Assertio Therapeutics
  • TEVA
  • Mylan
  • Arbor Pharma
  • Novartis
  • Apotex
  • Sun Pharmaceutical
  • Aurobindo Pharma
  • Intas
  • Amneal
  • Marksans Pharma
  • Glenmark
  • Alkem
  • Jiangsu Enhua
  • Jiangsu Hengrui
  • Sailike

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gabapentin Sales Value (2021-2032)
  4. 1.2.2 Global Gabapentin Sales Volume (2021-2032)
  5. 1.2.3 Global Gabapentin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gabapentin Market Dynamics
  1. 2.1 Gabapentin Industry Trends
  2. 2.2 Gabapentin Industry Drivers
  3. 2.3 Gabapentin Industry Opportunities and Challenges
  4. 2.4 Gabapentin Industry Restraints
3 Gabapentin Market by Company
  1. 3.1 Global Gabapentin Company Revenue Ranking in 2025
  2. 3.2 Global Gabapentin Revenue by Company (2021-2026)
  3. 3.3 Global Gabapentin Sales Volume by Company (2021-2026)
  4. 3.4 Global Gabapentin Average Price by Company (2021-2026)
  5. 3.5 Global Gabapentin Company Ranking (2024-2026)
  6. 3.6 Global Gabapentin Company Manufacturing Base and Headquarters
  7. 3.7 Global Gabapentin Company Product Type and Application
  8. 3.8 Global Gabapentin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gabapentin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gabapentin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gabapentin Market by Type
  1. 4.1 Gabapentin Type Introduction
  2. 4.1.1 Capsule
  3. 4.1.2 Tablet
  4. 4.2 Global Gabapentin Sales Volume by Type
  5. 4.2.1 Global Gabapentin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gabapentin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Gabapentin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Gabapentin Sales Value by Type
  9. 4.3.1 Global Gabapentin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Gabapentin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Gabapentin Sales Value Share by Type (2021-2032)
5 Gabapentin Market by Application
  1. 5.1 Gabapentin Application Introduction
  2. 5.1.1 Epilepsy
  3. 5.1.2 Neuropathic Pain
  4. 5.1.3 Restless Legs Syndrome
  5. 5.1.4 Others
  6. 5.2 Global Gabapentin Sales Volume by Application
  7. 5.2.1 Global Gabapentin Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gabapentin Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Gabapentin Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Gabapentin Sales Value by Application
  11. 5.3.1 Global Gabapentin Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gabapentin Sales Value by Application (2021-2032)
  13. 5.3.3 Global Gabapentin Sales Value Share by Application (2021-2032)
6 Gabapentin Regional Sales and Value Analysis
  1. 6.1 Global Gabapentin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gabapentin Sales by Region (2021-2032)
  3. 6.2.1 Global Gabapentin Sales by Region: 2021-2026
  4. 6.2.2 Global Gabapentin Sales by Region (2027-2032)
  5. 6.3 Global Gabapentin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gabapentin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gabapentin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gabapentin Sales Value by Region (2027-2032)
  9. 6.5 Global Gabapentin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gabapentin Sales Value (2021-2032)
  12. 6.6.2 North America Gabapentin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gabapentin Sales Value (2021-2032)
  15. 6.7.2 Europe Gabapentin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gabapentin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gabapentin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gabapentin Sales Value (2021-2032)
  21. 6.9.2 South America Gabapentin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gabapentin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gabapentin Sales Value Share by Country, 2025 VS 2032
7 Gabapentin Country-level Sales and Value Analysis
  1. 7.1 Global Gabapentin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gabapentin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gabapentin Sales by Country (2021-2032)
  4. 7.3.1 Global Gabapentin Sales by Country (2021-2026)
  5. 7.3.2 Global Gabapentin Sales by Country (2027-2032)
  6. 7.4 Global Gabapentin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gabapentin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gabapentin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gabapentin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gabapentin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gabapentin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gabapentin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gabapentin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gabapentin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gabapentin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gabapentin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gabapentin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gabapentin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gabapentin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gabapentin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gabapentin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gabapentin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gabapentin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gabapentin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gabapentin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gabapentin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gabapentin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gabapentin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gabapentin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gabapentin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gabapentin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gabapentin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gabapentin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gabapentin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gabapentin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gabapentin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gabapentin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gabapentin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gabapentin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gabapentin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gabapentin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gabapentin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gabapentin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gabapentin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gabapentin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gabapentin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gabapentin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gabapentin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gabapentin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gabapentin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gabapentin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gabapentin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gabapentin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gabapentin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gabapentin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gabapentin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gabapentin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gabapentin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gabapentin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gabapentin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gabapentin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gabapentin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gabapentin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gabapentin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gabapentin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gabapentin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gabapentin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gabapentin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gabapentin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gabapentin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gabapentin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gabapentin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gabapentin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gabapentin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gabapentin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gabapentin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gabapentin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gabapentin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gabapentin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gabapentin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gabapentin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gabapentin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gabapentin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gabapentin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gabapentin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gabapentin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gabapentin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gabapentin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gabapentin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gabapentin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gabapentin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gabapentin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Gabapentin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Gabapentin Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Assertio Therapeutics
  8. 8.2.1 Assertio Therapeutics Company Information
  9. 8.2.2 Assertio Therapeutics Business Overview
  10. 8.2.3 Assertio Therapeutics Gabapentin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Assertio Therapeutics Gabapentin Product Portfolio
  12. 8.2.5 Assertio Therapeutics Recent Developments
  13. 8.3 TEVA
  14. 8.3.1 TEVA Company Information
  15. 8.3.2 TEVA Business Overview
  16. 8.3.3 TEVA Gabapentin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 TEVA Gabapentin Product Portfolio
  18. 8.3.5 TEVA Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Gabapentin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Gabapentin Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Arbor Pharma
  26. 8.5.1 Arbor Pharma Company Information
  27. 8.5.2 Arbor Pharma Business Overview
  28. 8.5.3 Arbor Pharma Gabapentin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Arbor Pharma Gabapentin Product Portfolio
  30. 8.5.5 Arbor Pharma Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Gabapentin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Gabapentin Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Apotex
  38. 8.7.1 Apotex Company Information
  39. 8.7.2 Apotex Business Overview
  40. 8.7.3 Apotex Gabapentin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Apotex Gabapentin Product Portfolio
  42. 8.7.5 Apotex Recent Developments
  43. 8.8 Sun Pharmaceutical
  44. 8.8.1 Sun Pharmaceutical Company Information
  45. 8.8.2 Sun Pharmaceutical Business Overview
  46. 8.8.3 Sun Pharmaceutical Gabapentin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Gabapentin Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Recent Developments
  49. 8.9 Aurobindo Pharma
  50. 8.9.1 Aurobindo Pharma Company Information
  51. 8.9.2 Aurobindo Pharma Business Overview
  52. 8.9.3 Aurobindo Pharma Gabapentin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Aurobindo Pharma Gabapentin Product Portfolio
  54. 8.9.5 Aurobindo Pharma Recent Developments
  55. 8.10 Intas
  56. 8.10.1 Intas Company Information
  57. 8.10.2 Intas Business Overview
  58. 8.10.3 Intas Gabapentin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Intas Gabapentin Product Portfolio
  60. 8.10.5 Intas Recent Developments
  61. 8.11 Amneal
  62. 8.11.1 Amneal Company Information
  63. 8.11.2 Amneal Business Overview
  64. 8.11.3 Amneal Gabapentin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amneal Gabapentin Product Portfolio
  66. 8.11.5 Amneal Recent Developments
  67. 8.12 Marksans Pharma
  68. 8.12.1 Marksans Pharma Company Information
  69. 8.12.2 Marksans Pharma Business Overview
  70. 8.12.3 Marksans Pharma Gabapentin Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Marksans Pharma Gabapentin Product Portfolio
  72. 8.12.5 Marksans Pharma Recent Developments
  73. 8.13 Glenmark
  74. 8.13.1 Glenmark Company Information
  75. 8.13.2 Glenmark Business Overview
  76. 8.13.3 Glenmark Gabapentin Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Glenmark Gabapentin Product Portfolio
  78. 8.13.5 Glenmark Recent Developments
  79. 8.14 Alkem
  80. 8.14.1 Alkem Company Information
  81. 8.14.2 Alkem Business Overview
  82. 8.14.3 Alkem Gabapentin Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Alkem Gabapentin Product Portfolio
  84. 8.14.5 Alkem Recent Developments
  85. 8.15 Jiangsu Enhua
  86. 8.15.1 Jiangsu Enhua Company Information
  87. 8.15.2 Jiangsu Enhua Business Overview
  88. 8.15.3 Jiangsu Enhua Gabapentin Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Jiangsu Enhua Gabapentin Product Portfolio
  90. 8.15.5 Jiangsu Enhua Recent Developments
  91. 8.16 Jiangsu Hengrui
  92. 8.16.1 Jiangsu Hengrui Company Information
  93. 8.16.2 Jiangsu Hengrui Business Overview
  94. 8.16.3 Jiangsu Hengrui Gabapentin Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Jiangsu Hengrui Gabapentin Product Portfolio
  96. 8.16.5 Jiangsu Hengrui Recent Developments
  97. 8.17 Sailike
  98. 8.17.1 Sailike Company Information
  99. 8.17.2 Sailike Business Overview
  100. 8.17.3 Sailike Gabapentin Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Sailike Gabapentin Product Portfolio
  102. 8.17.5 Sailike Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gabapentin Value Chain Analysis
  2. 9.1.1 Gabapentin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gabapentin Sales Mode & Process
  6. 9.2 Gabapentin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gabapentin Distributors
  9. 9.2.3 Gabapentin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst